Oxygen Transfer on Substituted ZrO2, Bi2O3, and CeO2 Electrolytes with Platinum Electrodes II. A-C Impedance Study

An equivalent electrical circuit that describes the electrode processes on different electrolytes, using porous Pt electrodes,is given. Diffusional processes are important and have to be presented by Warburg components in the circuit. Theoverall electrode process is rate limited by diffusion of atomic oxygen on the electrode surface for stabilized zirconia andsubstituted ceria (low PO2). On stabilized bismuth sesquioxide diffusion of atomic oxygen on the electrolyte surface is ratelimiting at high PO2 while at low PO2 another process, probably diffusion of electronic species in the electrolyte, is dominant.One of these processes plays a role too on substituted ceria at high PO2, where a charge transfer process is dominant. Theseresults are consistent with the mechanisms developed in part I of this paper

High oxygen ion conduction in sintered oxides of the Bi2O3---Ln2O3 system

The conditions leading to optimum conductivity of the Bi2O3---Ln2O3 system were investigated. The highest conductivity was found for Ln = Er or Tm. Ordering in the oxygen lattice was investigated using neutron diffraction. Correlations were found between the neutron diffraction data and the conductivity

Preparation and properties of new oxygen ion conductors for use at low temperatures

Two new systems, Bi2O3---Er2O3 and ZrO2---Y2O3(CaO)---Bi2O3 were investigated. The first system has a homogeneous cubic, fluorite phase between 17.5 and 45.5 mol % Er2O3 and can be sintered to densities near 95% at 1200 K. At temperatures between 700 K and 1000 K the highest value of the a.c. oxygen ion conduction in this system is twice as much as the highest value found in the literature. In the second system concentrations of 1–3 mol % Bi2O3 act as an excellent sintering aid for ZrO2---Y2O3 and ZrO2---CaO samples which can be sintered to densities higher than 95% at temperatures of 1350 K. During this procedure a liquid ZrO2---Bi2O3 phase exists from which Bi2O3 partly evaporates with increasing sintering time. The oxygen ion conduction is little affected by the Bi2O3-rich second phase. The influence of annealing procedures up to 1570 K on the conduction in the ZrO2---Y2O3---Bi2O3 system is small despite weight losses up to 4%

Effect of grain boundaries on the conductivity of high-purity ZrO2---Y2O3 ceramics

Grain boundary conductivities are determined by complex impedance measurements (1–106 Hz) on high-purity ceramics prepared by the alkoxide synthesis and on less pure ceramics obtained from a commercial powder. The grain size was varied systematically in the region 0.36–55 μm. The grain boundary conductivity is strongly influenced by the grain size, impurities and cooling procedure. The grain boundary conductivity increases linearly with the grain size for small grain sizes (0.3 to 2–4 μm) and is constant for larger grain sizes. The calculated specific conductivity of the grain boundary for pure materials is about 100 times smaller than that of the bulk. The grain boundary thickness was estimated to be 5.4 nm. The activation energy of the grain boundary conductivity is 7 kJ mole−1 higher than of the bulk

Structure and conductivity of pyrochlore and fluorite type solid solutions

High oxygen conductivities can be achieved in cation ordered LnxZrl-x=xO2-l/2x (Ln=Gd, Nd) solid solutions with pyrochlore (P) structure. High values of the pre-exponential factor σo are correlated with the degree of anion disorder in the 8b oxygen sublattice (neutron diffraction). The activation energy ΔH is lowered by cation ordering (F-P transition; effect of ) due to the occurence of a preferential diffusion path. Maximum oxygen conductivity is achieved in (1−x)Bi2O3−x Ln2O3 solid solutions with fluorite related δ-Bi2O3 structure for Ln=Er and x=0.20. Neutron diffraction measurements indicate the occurence of short range ordering in “Er-O units” with relative small interatomic distances at T < 820 K. This leads to an increased activation energy

Structure and ionic conductivity of B_i2O₃ substituted with lanthanide oxides

A neutron diffraction study was performed on (Bi2O3)O.80(Er2O3)0.20 in the temperature region of 300–1100 K. There is no long-range ordering of vacancies. It is concluded from diffuse scattering that at low temperatures short-range ordering appears, leading to the occurrence of relatively short Ln-O distances. At temperatures above 870 K the oxygen lattice disorders.\ud \ud In the low temperature region of Bi2O3-Ln2O3 solid solutions with the δ-Bi2O3 structure the activation energy of the conductivity is determined by the strength of the Ln-O band. In the high temperature region the energy necessary for oxygen ions to migrate through the tetrahedron planes plays a role

Lack of uniform diagnostic criteria for cervical radiculopathy in conservative intervention studies: A systematic review

Purpose: Cervical radiculopathy (CR) is a common diagnosis. It is unclear if intervention studies use uniform definitions and criteria for patient selection. Our objective was to assess the uniformity of diagnostic criteria and definitions used in intervention studies to select patients with CR. Methods: We electronically searched the Cochrane Controlled Trials Register, MEDLINE, EMBASE and CINAHL. Studies were included when evaluating conservative interventions in randomised clinical trials (RCTs) in patients with CR. Selection criteria and definitions for patients with CR were extracted and evaluated on their uniformity. Results: Thirteen RCTs were included. Pain was used as an inclusion criterion in 11 studies. Inclusion based on the duration and location of pain varied between studies. Five studies used sensory symptoms in the arm as inclusion crite

The evolution of precision oncology:The ongoing impact of the Drug Rediscovery Protocol (DRUP)

Background and purpose: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered indication in patients with advanced or metastatic cancer. Patients: Patients with advanced or metastatic cancer are eligible when there are no standard of care treatment options left and the tumor possesses a molecular genomic variant for which commercially available anticancer treatment is accessible off-label in DRUP. Clinical benefit is the study’s primary endpoint, characterized by a confirmed objective response or stable disease after at least 16 weeks of treatment. Results: More than 2,500 patients have undergone evaluation, of which over 1,500 have started treatment in DRUP. The overall clinical benefit rate (CBR) remains 33%. The nivolumab cohort for patients with microsatellite instable metastatic tumors proved highly successful with a CBR of 63%, while palbociclib or ribociclib in patients with tumors harboring CDK4/6 pathway alterations showed limited efficacy, with a CBR of 15%. The formation of two European initiatives (PCM4EU and PRIME-ROSE) strives to accelerate implementation and enhance data collection to broaden equitable access to anticancer treatments and gather more evidence. Conclusion: DRUP persists in improving patients access to off-label targeted or immunotherapy in the Netherlands and beyond. The expansion of DRUP-like clinical trials across Europe provides countless opportunities for broadening the horizon of precision oncology.</p

The evolution of precision oncology:The ongoing impact of the Drug Rediscovery Protocol (DRUP)

Background and purpose: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered indication in patients with advanced or metastatic cancer. Patients: Patients with advanced or metastatic cancer are eligible when there are no standard of care treatment options left and the tumor possesses a molecular genomic variant for which commercially available anticancer treatment is accessible off-label in DRUP. Clinical benefit is the study’s primary endpoint, characterized by a confirmed objective response or stable disease after at least 16 weeks of treatment. Results: More than 2,500 patients have undergone evaluation, of which over 1,500 have started treatment in DRUP. The overall clinical benefit rate (CBR) remains 33%. The nivolumab cohort for patients with microsatellite instable metastatic tumors proved highly successful with a CBR of 63%, while palbociclib or ribociclib in patients with tumors harboring CDK4/6 pathway alterations showed limited efficacy, with a CBR of 15%. The formation of two European initiatives (PCM4EU and PRIME-ROSE) strives to accelerate implementation and enhance data collection to broaden equitable access to anticancer treatments and gather more evidence. Conclusion: DRUP persists in improving patients access to off-label targeted or immunotherapy in the Netherlands and beyond. The expansion of DRUP-like clinical trials across Europe provides countless opportunities for broadening the horizon of precision oncology.</p